Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to Post Q1 2024 Earnings of $0.44 Per Share, Zacks Research Forecasts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXFree Report) – Equities research analysts at Zacks Research reduced their Q1 2024 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a report issued on Wednesday, March 20th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of $0.44 per share for the quarter, down from their prior forecast of $0.69. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.57 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q2 2024 earnings at $0.55 EPS, Q3 2024 earnings at $0.61 EPS, Q4 2024 earnings at $0.65 EPS, FY2024 earnings at $2.23 EPS, Q1 2025 earnings at $0.64 EPS, Q2 2025 earnings at $0.67 EPS, Q3 2025 earnings at $0.66 EPS, Q4 2025 earnings at $0.66 EPS, FY2025 earnings at $2.64 EPS and FY2026 earnings at $3.31 EPS.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.04. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. The firm had revenue of $110.57 million for the quarter, compared to the consensus estimate of $105.78 million.

A number of other analysts also recently weighed in on CPRX. HC Wainwright restated a “buy” rating and issued a $24.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 1st. Bank of America began coverage on Catalyst Pharmaceuticals in a research note on Thursday, March 7th. They issued a “buy” rating and a $23.00 target price for the company. TheStreet upgraded Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Tuesday, March 12th. Oppenheimer assumed coverage on Catalyst Pharmaceuticals in a research note on Thursday, December 21st. They issued an “outperform” rating and a $30.00 target price for the company. Finally, StockNews.com raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus target price of $26.57.

Read Our Latest Report on CPRX

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $15.73 on Monday. Catalyst Pharmaceuticals has a fifty-two week low of $11.09 and a fifty-two week high of $18.22. The firm has a market capitalization of $1.85 billion, a PE ratio of 25.79, a price-to-earnings-growth ratio of 0.98 and a beta of 0.92. The stock’s 50-day simple moving average is $14.87 and its 200-day simple moving average is $14.11.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CPRX. Advisory Services Network LLC boosted its stake in shares of Catalyst Pharmaceuticals by 260.2% during the 1st quarter. Advisory Services Network LLC now owns 1,801 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 1,301 shares in the last quarter. Parkside Financial Bank & Trust acquired a new position in Catalyst Pharmaceuticals during the fourth quarter worth $31,000. VisionPoint Advisory Group LLC acquired a new position in Catalyst Pharmaceuticals during the second quarter worth $43,000. FMR LLC increased its position in Catalyst Pharmaceuticals by 24.2% during the second quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 822 shares during the last quarter. Finally, Covestor Ltd grew its position in shares of Catalyst Pharmaceuticals by 768.0% in the first quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,316 shares during the last quarter. 77.27% of the stock is owned by institutional investors.

About Catalyst Pharmaceuticals

(Get Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Featured Articles

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.